ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties

The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.